These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 24762281)

  • 1. Inhibitors - cellular aspects and novel approaches for tolerance.
    Scott DW
    Haemophilia; 2014 May; 20 Suppl 4(0 4):80-6. PubMed ID: 24762281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
    Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
    Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
    [No Abstract]   [Full Text] [Related]  

  • 3. The management of hemophilia patients with inhibitors.
    Nilsson IM
    Transfus Med Rev; 1992 Oct; 6(4):285-93. PubMed ID: 1421831
    [No Abstract]   [Full Text] [Related]  

  • 4. Key issues in inhibitor management in patients with haemophilia.
    Gomez K; Klamroth R; Mahlangu J; Mancuso ME; Mingot ME; Ozelo MC
    Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s319-29. PubMed ID: 24333092
    [No Abstract]   [Full Text] [Related]  

  • 5. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D; Rodgers GM
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract]   [Full Text] [Related]  

  • 6. The molecular basis of haemophilia A and B.
    Giannelli F; Green PM
    Baillieres Clin Haematol; 1996 Jun; 9(2):211-28. PubMed ID: 8800501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological aspects of inhibitor development.
    Reding MT
    Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 10. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
    Scharrer I
    Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How I manage patients with inherited haemophilia A and B and factor inhibitors.
    Ljung RCR
    Br J Haematol; 2018 Feb; 180(4):501-510. PubMed ID: 29270992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
    Shirahata A; Fukutake K; Higasa S; Mimaya J; Oka T; Shima M; Takamatsu J; Taki M; Taneichi M; Yoshioka A;
    Haemophilia; 2011 Sep; 17(5):771-6. PubMed ID: 21682824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
    Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
    Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation.
    Scott DW; Lozier JN
    Br J Haematol; 2012 Feb; 156(3):295-302. PubMed ID: 22055221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors in haemophilia: a primer.
    DiMichele DM
    Haemophilia; 2000 Jul; 6 Suppl 1():38-40. PubMed ID: 10982266
    [No Abstract]   [Full Text] [Related]  

  • 16. A study of prospective surveillance for inhibitors among persons with haemophilia in the United States.
    Soucie JM; Miller CH; Kelly FM; Payne AB; Creary M; Bockenstedt PL; Kempton CL; Manco-Johnson MJ; Neff AT;
    Haemophilia; 2014 Mar; 20(2):230-7. PubMed ID: 24261612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
    Mathias M; Khair K; Hann I; Liesner R
    Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.
    Gouw SC; van den Berg HM
    Semin Thromb Hemost; 2009 Nov; 35(8):723-34. PubMed ID: 20169509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to manage invasive procedures in children with haemophilia.
    Ljung RC; Knobe K
    Br J Haematol; 2012 Jun; 157(5):519-28. PubMed ID: 22390160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors in congenital haemophilia.
    Brettler DB
    Baillieres Clin Haematol; 1996 Jun; 9(2):319-29. PubMed ID: 8800508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.